Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174258
Title: | In vivo effects of romidepsin on T-Cell activation, apoptosis and function in the BCN02 HIV-1 kick&Kill clinical trial |
Author: | Rosas-Umbert, Miriam Ruiz-Riol, Marta Fernández, Marco A. Marszalek, Marta Coll, Pep Manzardo, Christian Cedeño, Samandhy Miró Meda, José M. Clotet, Bonaventura, 1953- Hanke, Tomás Moltó, José Mothe, Beatriz Brander, Christian |
Keywords: | Cèl·lules T Vacunació Apoptosi T cells Vaccination Apoptosis |
Issue Date: | 20-Mar-2020 |
Publisher: | Frontiers Media |
Abstract: | Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4+ T cells from HIV-1+ individuals on suppressive antiretroviral therapy. However, in vitro experiments suggested that RMD could also impair T-cell functionality, particularly of activated T cells. Thus, the usefulness of RMD in HIV-1 kick&kill strategies, that aim to enhance the immune system elimination of infected cells after inducing HIV-1 viral reactivation, may be limited. In order to address whether the in vitro observations are replicated in vivo, we determined the effects of RMD on the total and HIV-1-specific T-cell populations in longitudinal samples from the BCN02 kick&kill clinical trial (NCT02616874). BCN02 was a proof-of-concept study in 15 early treated HIV-1+ individuals that combined MVA.HIVconsv vaccination with three weekly infusions of RMD given as a latency reversing agent. Our results show that RMD induced a transient increase in the frequency of apoptotic T cells and an enhanced activation of vaccine-induced T cells. Although RMD reduced the number of vaccine-elicited T cells secreting multiple cytokines, viral suppressive capacity of CD8+ T cells was preserved over the RMD treatment. These observations have important implications for the design of effective kick&kill strategies for the HIV-1 cure. |
Note: | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2020.00418 |
It is part of: | Frontiers in Immunology, 2020, vol. 11, num. 418 |
URI: | http://hdl.handle.net/2445/174258 |
Related resource: | https://doi.org/10.3389/fimmu.2020.00418 |
ISSN: | 1664-3224 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
701138.pdf | 1.13 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License